Skip to main content

Psoriasis clinical trials at UCSF
7 in progress, 3 open to new patients

  • Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

    open to eligible people ages 18 years and up

    This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.

    San Francisco, California

  • Single Cell Genomics of Psoriatic Skin

    open to eligible people ages 18 years and up

    The purpose of this study is to understand how genetics play a role in psoriasis. Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this study aims to find out how it affects genetic and protein expression in patients with psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry and RNA-sequencing protocol.

    San Francisco, California

  • Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

    open to eligible people ages 6-17

    The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

    San Francisco, California and other locations

  • A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

    Sorry, not yet accepting patients

    This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.

    San Francisco, California and other locations

  • A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

    San Francisco, California and other locations

  • Chronic Plaque Psoriasis (Ps) Registry

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

    San Francisco, California and other locations

  • Immunologic Response to Secukinumab in Plaque Psoriasis

    Sorry, in progress, not accepting new patients

    This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.

    San Francisco, California

Last updated: